Global Cancer Supportive Care Therapeutics Market to Grow at 0.9% CAGR, Expects GBI Research in Its Report Published at MarketPublishers.com
16 May 2017 • by Natalie Aster
LONDON – Cancer supportive care products represent drugs that are used to prevent/treat different symptoms of cancer, and reduce adverse effects that are associated with cancer treatments. The main role of these drugs is to improve the overall quality of life of cancer patients.
At present, the number of people who suffer from cancer is rising. So, the interest in cancer supportive care products is set to skyrocket in the forthcoming years.
The level of unmet needs in the cancer supportive care therapy field is different across different indications. CINV and CIN boast treatment regimens that can help to notably decrease the incidence rate. Still, the level of the unmet needs for cancer pain, bone metastasis, etc. is high, as treatment is mainly utilized to alleviate the symptoms.
The market for cancer supportive care was worth USD 11.7 billion in 2015. It is expected to grow at a CAGR of just under 1% in the coming years. It is forecast to amount to USD 12.4 billion in 2022.
In-demand research report “Global Cancer Supportive Care Therapeutics Market to 2022” drawn up by our market research partner, GBI Research, offers a comprehensive discussion of the world’s market for cancer supportive care therapeutics. The study starts with an all-round overview of the therapy area.
It sheds light on the epidemiology, pathophysiology, and etiology. The report investigates symptoms, diagnosis, grading, and treatment. The research study casts light on major marketed products: Neulasta, Xofigo, Neupogen, Xgeva, and more.
It assesses the pipeline landscape and the market sizing. The research report focuses on the generic penetration and forecasts revenue trends. The study investigates the competitive environment and analyzes each company’s position.
It also concentrates on strategic consolidations and features future projections for the global marketplace through 2022.
More insightful studies by our partner can be found at its page.